Close Menu

Eli Lilly

By Turna Ray
Qiagen and Eli Lilly have partnered to develop and commercialize a molecular diagnostic that will help pick out best responders to a blood cancer drug that is in early development in Lilly's pipeline.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today announced a deal with Eli Lilly to develop a companion diagnostic for an investigational compound the drug manufacturer is developing for blood cancers.

By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.

By Adam Bonislawski
Drug companies are no strangers to protein biomarkers, with pharma firms exploring their use for tasks like measuring drug efficacy and selecting patient cohorts for clinical trials.

Thus far, the company has inked collaborative agreements with laboratories at the MD Anderson Cancer Center and Dartmouth Medical College to develop various multi-marker oncology assays; and is pursuing partnerships with pharmaceutical companies to explore using the platform in companion diagnostic development.

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.